The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Meta-analysis of anti-VEGF class adverse events from three double-blind (Db) placebo (Pbo)-controlled phase III trials with IV aflibercept (Afl).
Carmen Joseph Allegra
Consultant or Advisory Role - Roche/Genentech; Sanofi
Josep Tabernero
Consultant or Advisory Role - Sanofi
Philippe Rougier
Consultant or Advisory Role - Sanofi
Honoraria - Merck; Pfizer
Research Funding - SERVIER
Giorgio Scagliotti
Consultant or Advisory Role - AstraZeneca; Lilly
Honoraria - Lilly; Pfizer; Roche
Philip Agop Philip
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Radek Lakomy
No relevant relationships to disclose
Rodryg Ramlau
No relevant relationships to disclose
Sylvie Assadourian
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Soazig Chevalier
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Eric Van Cutsem
Research Funding - Sanofi